Polypharmacy. by unknown
STEWART, D., BENNIE, M. and MAIR, A. 2018. Polypharmacy. Briefing paper 13, version 13.1. Glasgow: 
Scottish School of Primary Care [online]. Available from: 
http://www.sspc.ac.uk/media/media_617129_en.pdf  
Polypharmacy. 
STEWART, D., BENNIE, M., MAIR, A. 
2018 
This document was downloaded from 
https://openair.rgu.ac.uk 
1 
(version 13.1, 27 August 2018) 
 
In-
side  
 
Scottish School of Primary Care 
Polypharmacy 
Briefing  
Paper 13 
Scottish School of Primary Care 
General Practice & Primary Care, 
Institute of Health & Wellbeing, 
College of MVLS,  
University of Glasgow, 
1 Horselethill Road,  
GLASGOW G12 9LX 
Email: info@sspc.ac.uk 
Polypharmacy 
Derek Stewart, 
Professor of Pharmacy Practice, 
School of Pharmacy and Life 
Sciences, Robert Gordon University 
d.stewart@rgu.ac.uk 
Marion Bennie, Professor of  
Pharmacy, University of Strathclyde/Chief 
Pharmacist, Information Services Division, 
NHS National Services Scotland 
marion.bennie@strath.ac.uk 
Alpana Mair, Head of Effective Prescribing & 
Therapeutics, Scottish Government 
alpana.mair@gov.scot 
2 
(version 13.1, 27 August 2018) 
 
 
.  
 
 
 
 
 
 
 
 
 
 
The Problem 
Multimorbidity, ‘the co-occurrence of two or more 
chronic medical conditions in one person’ poses many 
challenges to patient care and is recognised as a glob-
al challenge.1 Scottish epidemiological data highlight 
that almost one quarter of all patients are multimorbid, 
with prevalence increasing substantially with age and 
with socioeconomic status.2-5 Multimorbidity impacts 
the number of medicines prescribed. It is now well-
recognised that single disease guidelines are based on 
evidence from research that excludes most people with 
multimorbidity, and that the cumulative impact of single 
disease guideline recommendations often results in 
overwhelming medicines burden.6,7  
Figure 1 provides analysis of 2017 Scottish national 
prescribing data by age, highlighting that the number of 
medicines dispensed increases markedly with age. Just 
under 30% of those aged 85 years and above are re-
ceiving more than ten medicines.  
Figure 1. Number of distinct medicines dispensed in Scotland by five year age groups, January – June 2017 (image courtesy 
of ISD, NHS Scotland). The count of medicines is based on the number of different BNF paragraphs from which drugs were 
dispensed to each patient within the relevant time period. Patients may be prescribed one or more drugs from the same BNF 
paragraph, counts of numbers of BNF paragraphs will count each BNF paragraph only once, irrespective of how many drugs 
were prescribed from that paragraph. 
Improvement Topic Series 
The improvement topic series is a set of briefing pa-
pers about  areas of quality and safety which general 
practice clusters could usefully focus improvement 
activity on.  They summarise research, guideline and 
other evidence about areas of care which can be im-
proved, and improvement methods and interventions. 
 
Improvement Topic 4 
Polypharmacy in Primary Care 
Multimorbidity and inappropriate polypharmacy impact 
patient care, with consequences of drug-drug interac-
tions and adverse drug events, drug-related hospitali-
sations, non-adherence and higher health care costs.  
Decisions on starting and stopping medicines in older 
people are complex due to a number of factors includ-
ing the plethora of single disease guidelines which are 
based on evidence from research that largely excludes 
most people with multimorbidity.  This paper describes 
measures and improvement methods being imple-
mented in the real-world in Scottish general practice. 
3 
(version 13.1, 27 August 2018) 
 
 
 
 
 
 
 
Figure 2. Percentage of population aged 50 years and older 
dispensed ten or more distinct medicines in Scotland, includ-
ing at least one high risk medicine*, January – June 2017 
(image courtesy of ISD, NHS Scotland). *High risk medi-
cines are those that fall within the categories identified by 
Pirmohamed et al. Adverse drug reactions as cause of ad-
mission to hospital: prospective analysis of 18 820 patients 
BMJ 2004;329:15-19 
Polypharmacy, the prescribing of multiple medicines, 
has been labelled as ‘one of the greatest prescribing 
challenges’.8,9 Polypharmacy: 
 increases the likelihood of drug-drug interac-
tions and adverse drug events10,11 
 increases drug-related hospitalisations12 
 contributes to non-adherence13, and  
 leads to higher health care costs14. 
These issues are of particular concern in older people, 
as is evident from Figure 3. 
Figure 3, reproduced with permission from the Scottish Gov-
ernment Polypharmacy Model of Care Group, 2018  
Figure 2 gives data for those aged 50 years and over prescribed ten or more medicines and one or 
more high risk medicines.  
Historically, polypharmacy was commonly defined as 
the use of four or five different prescribed medi-
cines.15,16 More recently, the terms ‘inappropriate 
polypharmacy' (prescribing of multiple medicines 
which are either inappropriate or no longer indicated) 
and `appropriate' or `optimal polypharma-
cy' (appropriate prescribing of multiple medicines) 
have been suggested.17 In Scotland, these defini-
tions have been endorsed and extended as fol-
lows.18  
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International action to improve 
polypharmacy management 
In 2017, the World Health Organization launched a 
global initiative, Medication Without Harm, aiming to 
reduce the level of severe, avoidable harm related to 
medicines by 50% over the next five years.19 While 
the need to tackle inappropriate polypharmacy and 
promote appropriate polypharmacy is clear, several 
recent systematic reviews and meta-analyses on ap-
proaches to addressing inappropriate polypharmacy 
concluded that there was no convincing evidence of 
effectiveness on clinically relevant endpoints.20-22  
 
Project SIMPATHY (Stimulating Innovation Manage-
ment of Polypharmacy and Adherence in the Elderly) 
sought to address the issue of inappropriate 
polypharmacy (and related non-adherence) in older 
patients across the European Union (EU) by stimu-
lating and supporting innovation around polypharma-
cy management.23-25 SIMPATHY culminated in the 
launch of ‘Polypharmacy Management by 2030: A 
Patient Safety Challenge’26. The report, ‘sets out the 
case for prioritising working together now to address 
inappropriate medication use over the next decade, 
to ensure the quality, economic and political systems 
are put in place to improve medication safety for pa-
tients’. This work has identified six key recommenda-
tions to improve medication safety of which 
polypharmacy is an essential element. These findings 
have characterised and endorsed the strength of di-
rection of travel in Scotland. 
 
 
 
 
 
 
 
 
Appropriate polypharmacy is present, when 
A.  all drugs are prescribed for the purpose of 
achieving specific therapeutic objectives that 
have been agreed with the patient 
B.  therapeutic objectives are actually being 
achieved or there is a reasonable chance 
they will be achieved in the future 
C.  drug therapy has been optimised to minimise 
the risk of adverse drug reactions (ADRs) 
and, 
D.  the patient is motivated and able to take all 
medicines as intended. 
  
Inappropriate polypharmacy is present, when one 
or more drugs are prescribed that are not or no long-
er needed, either because: 
A.  there is no evidence based indication, the 
indication has expired or the dose is unnec-
essarily high 
B.  one or more medicines fail to achieve the 
therapeutic objectives they are intended to 
achieve 
C.  one, or the combination of several drugs 
cause unacceptable ADRs, or put the patient 
at an unacceptably high risk of such ADRs, 
or because 
D.  the patient is not willing or able to take one or 
more medicines as intended. 
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Implementation in real life NHS practice in 
Scotland 
In 2018 the Scottish Government published Polyphar-
macy Guidance, Realistic Prescribing, 3rd edition, gen-
erated through the collaborative efforts of clinicians, 
academics and policy makers from across Scotland.18 
The ambition is to reduce drug related harm through 
the collective efforts of all; centred on shared decision 
making between the patient (and/or carers) and their 
clinician(s), supported by the resources and intelli-
gence available through our advancing health and so-
cial care systems. This precis of the guidance navi-
gates clinicians through the guidance and help them to 
apply the principles within their day-to-day practice. 
Guidance is available as 
 PDF guidance, https://
www.therapeutics.scot.nhs.uk/wp-content/
uploads/2018/04/Polypharmacy-Guidance-
2018.pdf 
 Online guidance, http://
www.polypharmacy.scot.nhs.uk/ 
 Professional app, 
www.polypharmacy.scot.nhs.uk 
 Patient app, www.polypharmacy.scot.nhs.uk  
Which patients to target for review? 
Evolving evidence indicates risk of harm from medi-
cines with increasing age, frailty, multiple medicines 
and high risk medicines.  Outlined below are the  crite-
ria recommended to assist in prioritising patients for a 
polypharmacy review.   
These can be more refined by considering particular 
age bands (e.g. >75yrs), frailty (HIS Frailty / SPARRA 
score) or dominant condition (e.g. dementia). The 
guidance also outlines a range of high risk medicines 
( page 10)  and/or combinations (including NSAIDs, 
anticoagulants, methotrexate, ACEI/ARB – see Appen-
dix E, https://www.therapeutics.scot.nhs.uk/wp-
content/uploads/2018/04/Polypharmacy-Guidance-
2018.pdf ). Search templates and reports are available 
for both local and national systems  to assist with pa-
tient case finding. 
When should patients be targeted ?  
 
Review of patients should be embedded within routine 
care at any point which involves medicines. It may be 
helpful to think of this at the following five stages in the 
health care process: 
 Prescribing (and risk assessment)  
 Medication review  
 Dispensing and administration  
 Communication and patient engagement  
 Medication reconciliation (at care transitions)  
 
How should patients be reviewed?  
 
The guidance provides a useful 7-Steps approach to 
guide a medication review, placing the patient at the 
centre supported by their clinician(s) and the resources 
to enable safe and effective medicines use.  
 
 
 
 
 
 
 
 
 
 
Key Recommendations 
 1. Use a systems approach that has multidisciplinary clinical 
and policy leadership 
2. Nurture a culture that encourages and prioritises the safety 
and quality of prescribing 
3. Ensure that patients are integral to the decisions made about 
their medicines and are empowered and supported to do so 
4. Use data to drive change and measure outcomes 
5. Adopt an evidence based approach with a bias towards action 
6. Utilise, develop and share tools to support implementation 
 
  
  
A. Aged 50 years and older and resident in a care home, 
regardless of the number of medicines prescribed  
B. Approaching the end of their lives: adults of any age, 
approaching the end of their life due to any cause, are likely 
to have different medication needs, and risk versus benefit 
discussions will often differ from healthy adults with longer 
expected life spans.  
C. Prescribed ten or more medicines irrespective of age 
(identifies those from deprived communities where the aver-
age age is lower when taking 10 or more medications)  
D. On high-risk medication, regardless of the number of 
medicines taken . 
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  Steps Process 
Aims 1. What matters 
to the patient? 
Review diagnoses and identify therapeutic objectives with respect to: 
What matters to me (the patient)? 
Understanding of objectives of drug therapy 
Management of existing health problems 
Prevention of future health problems 
  
Need 2. Identify essen-
tial drug therapy 
Identify essential drugs (not to be stopped without specialist advice): 
Drugs that have essential replacement functions (e.g. levothyroxine) 
Drugs to prevent rapid symptomatic decline (e.g. drugs for Parkinson’s dis-
ease, heart failure) 
  
3. Does the pa-
tient take unnec-
essary drug ther-
apy? 
Identify and review the (continued) need for drugs: 
With temporary indications 
With higher than usual maintenance doses 
With limited benefit in general for the indication they are used for 
With limited benefit in the patient under review 
  
Effectiveness 4. Are therapeutic 
objectives being 
achieved? 
Identify the need for adding/intensifying drug therapy in order to achieve 
therapeutic objectives: 
To achieve symptom control 
To achieve biochemical/clinical targets 
To prevent disease progression/exacerbation 
  
Safety 5. Does the pa-
tient have ADR/
side effects or is 
at risk of ADRs/
side effects? 
Does the patient 
know what to do 
if they’re ill? 
Identify patient safety risks by checking for: 
Drug-disease interactions 
Drug-drug interactions 
Robustness of monitoring mechanisms for high-risk drugs 
Drug-drug and drug-disease interactions 
Risk of accidental overdosing 
  
Identify adverse drug effects by checking for 
Specific symptoms/laboratory markers (e.g. hypokalaemia) 
Cumulative adverse drug effects 
Drugs that may be used to treat ADRs caused by other drugs 
 
Cost-
effectiveness 
6. Is drug therapy 
cost-effective? 
Identify unnecessarily costly drug therapy by: 
Consider more cost-effective alternatives (but balance against effective-
ness, safety, convenience) 
  
Patient centred-
ness 
7. 
Is the patient 
willing and able to 
take drug therapy 
as intended? 
Does the patient understand the outcomes of the review? 
Does the patient understand why they need to take their medication? 
Consider Teach back 
  
Ensure drug therapy changes are tailored to patient preferences 
Is the medication in a form the patient can take? 
Is the dosing schedule convenient? 
Consider what assistance the patient might have and when this is available 
Is the patient able to take medicines as intended? 
  
Agree and Communicate Plan 
Discuss with the patient/carer/welfare proxy therapeutic objectives and 
treatment priorities 
Decide with the patient/carer/welfare proxies what medicines have an effect 
of sufficient magnitude to consider continuation or discontinuation 
Inform relevant healthcare and social care carers change in treatments 
across the care interfaces 
  
Add the READ code 8B31B to the patients record so that when they move 
across transitions of care it is clear their medication has been reviewed 
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How to monitor the impact of polyphar-
macy reviews  
In Scotland, suite of 17 indicators of prescribing ap-
propriateness have been developed, using the na-
tional Prescribing Information System. An example is 
shown illustrating the impact of the Scottish 
polypharmacy guidance on the reduction of specific 
harmful combinations. The indicators are available in 
the Discovery data platform http://
www.nssdiscovery.scot.nhs.uk/ at Health Board, GP 
Practice and GP Cluster level.  
Role of the patient and development of 
the ‘Patient App’  
The updated guidance builds on the patient centred 
approach by ensuring that the review is considered 
from the patients perspective, by first asking the 
question “What Matters to you?”. The aim is to em-
power the patient to take part in the shared decision 
making around medicines use and review. The 
polypharmacy app 
www.polypharmacy.scot.nhs.uk  was previously 
available for clinicians but the updated app now in-
cludes a patient tool that provides shared decision 
making tools such as information on numbers need-
ed to treat for patients. This has been developed 
with the health literacy team and supports the princi-
ples of realistic medicines and shared decision mak-
ing.  
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Clinical outcome measures are also under develop-
ment, combining prescribing information together 
with SMR01 data. The use of hospital admission 
data is being explored in certain situations as a 
measure of clinical outcome following polypharmacy 
reviews is being explored, recognising the potential 
lack of direct association between review and admis-
sion. Further work is underway exploring the devel-
opment of clinical decision support tools using the 
richness of data being collected by current and 
evolving clinical systems. Innovative solutions could 
be embedded in these systems to support continu-
ous review of patients’ medicines as their clinical 
conditions change in real time. For example, there 
amy be potential to scan patient information and da-
ta in real time to signal changing risk profile prompt-
ing review.    
Implications for collaborative quality im-
provement in general practice clusters 
While the management of polypharmacy in multimor-
bid individuals is not straightforward, various 
measures and tools described throughout this paper 
are readily available for use within GP practices and 
clusters. If you have not already done so, download 
the Polypharmacy Guidance, Realistic Prescribing, 
and the Professional and patient apps. Review and 
reflect on the approaches take in your practice and 
cluster around the identification and management of 
those with potentially inappropriate polypharmacy. 
Also consider how you can better promote appropri-
ate polypharmacy in each contact with those with 
multimorbidity. The Discovery data platform was 
launched at the start of October 2018 and can be 
used to map performance against the national indi-
cators over time  
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